Expression of IgG Monoclonals with Engineered Immune Effector Functions
The therapeutic development of monoclonal antibodies requires robust and reliable methods for their recombinant expression and characterization. In this context, an increasingly important aspect in the antibody development process is to determine the contribution of Fc-mediated immune effector functions to therapeutic activity. Here we describe steps for the cloning and mammalian expression of mouse and human IgG monoclonals with reduced immune effector functions, based on mutation of Fc-gamma receptor and complement-binding sites. The resulting antibody preparations contain low levels of endotoxin and are suitable for testing in animal models of disease.
|ISBN||1940-6029 (Electronic) 1064-3745 (Linking)|
|Authors||Vazquez-Lombardi, R.; Nevoltris, D.; Rouet, R.; Christ, D.|
|Responsible Garvan Author|
|Publisher Name||Methods in Molecular Biology|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/30196504|